The site also highlights the Company's progress in developing a gestational diabetes screening test, as the exclusive licensee granted by UCLA. The non-invasive, highly accurate streamline test mitigates the lengthy process of diagnoses and would more quickly treat the glucose intolerant disease, which potentially impacts 4.3 million pregnant women each year.

Along with background about types of stem cells and factoids, the new site also reviews Entest BioMedical's focus on the promising field of in vitro expansion of adult stem cells using other types of cells, such as peripheral stem cells and cord blood stem cells to treat cancer and other diseases. The R & D company is also exploring isolating hematopoietic stem cells from peripheral blood or bone marrow and differentiating them into immune cells, especially T cells.

'Our new Web site demonstrates Entest BioMedical's mission and key scientific personnel who are dedicated to discovering and developing new procedures, treatments and medical devices that improve the quality of life - leading research and technology that serve the present and help shape the future,' said David Koos, Ph.D., DBA, Chairman and CEO.

About Entest BioMedical, Inc.

Entest BioMedical, Inc., a wholly-owned subsidiary of Bio-Matrix Scientific Group, Inc. (OTC BB: BMSN) formed in April 2009, focuses on research and development of traumatic brain injury (TBI) and spinal cord injury using autologous 'adipose-derived' stem cells. Entest BioMedical is involved with R&D activities relating to stem cell therapies, diabetes testing and medical devices.

Disclaimer

This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

SOURCE Entest BioMedical, Inc.